STAAR Surgical soars after company reported preliminary sales that crushed expecations
STAAR Surgical rose more than 20% in premarket trading after it gave preliminary Q1 sales numbers that crushed Wall Street expectations, which it attributed to booming sales in China and the Americas.
The company, which sells eye implants, said in a press release published Wednesday that it expects to report revenue north of $90 million in the current quarter, compared to the $73 million analysts polled by FactSet are currently penciling in.
The company said sales in China "accounted for the majority of the increase in net sales, along with continued double-digit growth in the Americas." It also noted that sales in the Middle East "were negatively affected by significant geopolitical and macroeconomic challenges, resulting in a decline in sales in parts of those regions."
The stock is up nearly 21% as of 6:25 a.m. ET, having fallen more than 11% from the start of the year to yesterday’s close.